Reimbursement agencies are increasingly likely to require some economic data to back the claims on the superior value of biotech drugs compared to traditional ones.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Author notes
Additional reporting by Alla Katsnelson, New York.
- Alla Katsnelson
Related links
Related links
Related links in Nature Research
Therapeutic area influences drug development costs
EU to review rare disease drugs market exclusivity
New rules for US drug reimbursement
Related external links
Rights and permissions
About this article
Cite this article
Sheridan, C., Katsnelson, A. Cost-effectiveness data on biologics needed. Nat Biotechnol 23, 272–273 (2005). https://doi.org/10.1038/nbt0305-272
Issue Date:
DOI: https://doi.org/10.1038/nbt0305-272
- Springer Nature America, Inc.
This article is cited by
-
Socio-economic aspects of neuroimmunological diseases
Journal of Neurology (2006)